Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LSVWJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD47M
|
|||||
| Synonyms |
SGN-CD47M; SGN CD47M; SGNCD47M
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Phase 1 (terminated/withdrawn)
|
|||||
| Antibody Name |
Humanized anti-CD47 IgG1 mAb
|
Antibody Info | ||||
| Antigen Name |
Leukocyte surface antigen CD47 (CD47)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Metalloproteinases cleavable linker
|
Linker Info | ||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Colorectal cancer |
1 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|
||||||||
| Melanoma |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Sarcoma |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 322 | ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 600 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Maximum Observed Concentration (Cmax) | 475 | ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1279 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Maximum Observed Concentration (Cmax) | 707 | ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1751 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2, AUC0-21day.
|
[1] |
| Maximum Observed Concentration (Cmax) | 591 | ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1515 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean, AUC0-21day.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 600 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Volume of Distribution (Vd) | 40 | mL/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1279 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Volume of Distribution (Vd) | 40 | mL/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1751 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2, AUC0-21day.
|
[1] |
| Volume of Distribution (Vd) | 29 | mL/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1515 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean, AUC0-21day.
|
[1] |
| Volume of Distribution (Vd) | 35 | mL/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 600 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1279 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1751 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2, AUC0-21day.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1515 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean, AUC0-21day.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 2 | day |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 600 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Clearance (CL) | 17 | mL/day/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.
|
[1] |
| Elimination Half-Life (t1/2) | 2.1 | day |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1279 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1, AUC0-21day.
|
[1] |
| Clearance (CL) | 15 | mL/day/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.
|
[1] |
| Elimination Half-Life (t1/2) | 1.3 | day |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1751 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2, AUC0-21day.
|
[1] |
| Clearance (CL) | 11 | mL/day/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.
|
[1] |
| Elimination Half-Life (t1/2) | 1.7 | day |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1515 | day*ug/mL |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean, AUC0-21day.
|
[1] |
| Clearance (CL) | 13 | mL/day/kg |
Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.
|
[1] |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1) must have specified metastatic solid tumors and measurable disease, with adequate contraception required. Key exclusions include prior CD47/SIRPalpha therapy, active CNS metastases, HIV/hepatitis infections, recent transfusions or immunosuppression, and cardiovascular events within 6 months. Life expectancy must exceed 12 weeks.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03957096 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study will assess safety parameters including adverse events and laboratory abnormalities over 24 months, with dose-limiting toxicities evaluated specifically within the first 28 days of treatment.
|
||||
| Other Endpoint |
Efficacy evaluations will include ORR, DOR, PFS and OS according to both RECIST v1.1 and iRECIST criteria, with assessments continuing for up to 4 years. Pharmacokinetic measurements (AUC, Cmax, Tmax, Ctrough) and immunogenicity (ADA) will be monitored for 24 months.
|
||||
References